Calidi Biotherapeutics Reveals Promising Virotherapy Data

Calidi Biotherapeutics ( (CLDI) ) has provided an update.

Calidi Biotherapeutics has unveiled promising data showcasing its innovative RTNova systemic virotherapy technology, designed to effectively target metastatic lung cancer and other oncology indications. By utilizing a novel strain of vaccinia virus, RTNova overcomes challenges like rapid immune clearance, offering robust potential in treating and possibly transforming tumor environments. This advancement signifies a potential breakthrough in antitumor therapies, with opportunities for collaborative ventures with pharmaceutical partners.

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.